IntrinsicIntrinsic
← All summaries

BICYCLE THERAPEUTICS PLC

BCYC
Financials & Chart →

Business Summary

Bicycle Therapeutics PLC is a clinical-stage pharmaceutical company focused on developing a novel class of medicines called Bicycle® molecules for diseases with unmet therapeutic needs. These molecules are fully synthetic short peptides designed to combine the pharmacological properties of biologics with the manufacturing and pharmacokinetic advantages of small molecules . The company's core business model revolves around leveraging its proprietary phage display screening platform to identify and optimize Bicycle molecules for various therapeutic applications, primarily in oncology, and through collaborations in other disease areas . Revenue is generated from these research collaborations, with the potential for future product sales if candidates achieve marketing approval .

The company's internal programs are concentrated on oncology. Nuzefatide pevedotin (formerly BT5528), a Bicycle Drug Conjugate (BDC®) targeting Ephrin type A receptor 2 (EphA2), is being evaluated in an ongoing company-sponsored Phase I/II clinical trial for advanced solid tumors and an ongoing company-sponsored Phase II clinical trial for recurrent metastatic pancreatic ductal adenocarcinoma . BT1702, a Bicycle Radioconjugate (BRC®) targeting Membrane Type 1 matrix metalloproteinase (MT1-MMP) with a lead-212 radioisotope payload, is currently undergoing Investigational New Drug (IND)-enabling activities . The company also develops Bicycle Imaging Agents (BIA molecules) to derisk novel targets and triage cancer indications . Zelenectide pevedotin, a BDC molecule targeting Nectin-4, was being evaluated in multiple clinical trials, including a Phase II/III registrational trial (Duravelo-2) for metastatic urothelial cancer and Phase I/II trials for NECTIN4 amplified advanced breast cancer and non-small cell lung cancer . However, in March 2026, the company announced a strategic reprioritization, converting Duravelo-2 to a randomized Phase II trial and deprioritizing it for internal development, while discontinuing the Phase I/II trials for breast and lung cancer . BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, is in a company-sponsored Phase I/II clinical trial, with plans to explore partnership opportunities after reporting combination data in the first half of 2026 .

For the fiscal year ended December 31, 2025, the company reported a net loss of $219.0 million . This follows net losses of $169.0 million in 2024 and $180.7 million in 2023 . As of December 31, 2025, the accumulated deficit stood at $899.8 million . The company's cash and cash equivalents were $628.1 million as of December 31, 2025 .

The strategic reprioritization announced in March 2026 represents a significant operational development. This includes focusing on nuzefatide pevedotin and next-generation Bicycle conjugates, including BRC molecules, while deprioritizing zelenectide pevedotin for internal development and discontinuing its trials in breast and lung cancer . Additionally, a proposed workforce reduction of approximately 30% of the workforce is being implemented, expected to reduce annual operating expenses by approximately 50% based on current plans . This workforce reduction was substantially completed in the fourth quarter of 2025, incurring aggregate charges of approximately $5.3 million for severance and other employee termination benefits during the year ended December 31, 2025 . An additional $8.0 million in aggregate charges for severance and employee termination benefits is expected from the March 2026 workforce reduction, to be substantially completed by the end of 2026 .

Business Outlook

Management's strategic reprioritization, announced in March 2026, aims to focus on promising next-generation therapeutics, specifically nuzefatide pevedotin and next-generation Bicycle conjugates, including BRC molecules . This reprioritization is expected to reduce annual operating expenses by approximately 50% based on current plans .

A major growth area is the continued development of nuzefatide pevedotin, a BDC molecule targeting EphA2. It is currently in an ongoing company-sponsored Phase I/II clinical trial for advanced solid tumors and an ongoing company-sponsored Phase II clinical trial for recurrent metastatic pancreatic ductal adenocarcinoma, which commenced recruiting patients in the first quarter of 2026 . Data for nuzefatide pevedotin in combination with nivolumab in patients with metastatic urothelial cancer are planned for presentation at a scientific conference in the first half of 2026 . Additional information regarding the pancreatic ductal adenocarcinoma indication will also be presented at a scientific conference in the first half of 2026 .

Another significant growth vector is the advancement of the Bicycle Radioligands Pipeline. IND-enabling activities are ongoing for BT1702, a theranostic BRC molecule targeting MT1-MMP with a 212 Pb radioisotope payload, with plans to initiate the first company-sponsored radioligand clinical trial for BT1702 in 2027 . The company is also developing BRC molecules targeting novel targets, including EphA2, with lead optimization activities ongoing . First human imaging data for an early BIA molecule targeting EphA2 were presented in November 2025, with additional data planned for presentation in the first half of 2026 . The company has established arrangements for a sustainable radioisotope supply chain, including an agreement with Eckert & Ziegler for radioisotope supply and development/manufacture of BRC and BIA molecules . Furthermore, a 15-year contract with the UK Nuclear Decommissioning Authority (UKNDA) for access to up to 400 tonnes of reprocessed uranium, and a collaboration with United Kingdom National Nuclear Laboratory (UKNNL) to extract thorium-228 (228 Th) for 212 Pb generators being developed by SpectronRx, are in place to support the supply of 212 Pb .

Operationally, the strategic reprioritization includes a proposed workforce reduction of approximately 30% of the workforce, expected to be substantially completed by the end of 2026 . This is anticipated to result in aggregate charges of approximately $8.0 million for severance and other employee termination benefits . The company's strategy also involves leveraging its proprietary screening platform to grow its pipeline and collaborating strategically with leading organizations to expand the application of its novel Bicycle modality to indications beyond oncology . For instance, ION826 (AZD4063), an investigational medicine incorporating a TfR1 Bicycle molecule under the collaboration agreement with Ionis, entered Phase I development in December 2025 .

Planned capital allocation includes continued R&D spending for internal programs and collaborations. The company believes its existing cash and cash equivalents of $628.1 million as of December 31, 2025, will fund operating expenses and capital expenditure requirements for at least 12 months from the filing date of the Annual Report .

Management explicitly flagged several structural headwinds and execution risks. The company has a history of significant operating losses, with net losses of $219.0 million in 2025, and expects to incur significant and increasing losses for the foreseeable future, potentially never achieving or maintaining profitability . There is a need for substantial additional funding, and an inability to raise capital when needed could force delays, reductions, or elimination of product discovery, development, or commercialization efforts . The company is substantially dependent on the success of its BDC and BRC programs, which may not successfully complete clinical trials, receive regulatory approval, or be commercialized . The product candidates represent a new category of medicines and may face heightened regulatory scrutiny . Difficulties in patient enrollment for clinical trials could cause delays . Results from preclinical studies and early clinical trials may not be predictive of future clinical trial outcomes . Undesirable side effects from product candidates could halt development, prevent approval, or limit commercial potential . The company may also be delayed or unsuccessful in identifying additional product candidates .

Risk Factors

The company faces several material risks, including significant operating losses, with a net loss of $219.0 million for the year ended December 31, 2025, and an accumulated deficit of $899.8 million , indicating a need for substantial additional funding. The success of its internal development programs, particularly BDC and BRC molecules, is uncertain, as they may not successfully complete clinical trials, receive regulatory approval, or be commercialized . The novel nature of Bicycle molecules may lead to heightened regulatory scrutiny . Operational risks include difficulties in patient enrollment for clinical trials, which could cause delays , and the unpredictability of preclinical and early clinical trial results, which may not be predictive of future success . Product candidates may cause undesirable side effects, potentially halting clinical development, preventing marketing approval, or limiting commercial potential . The company relies heavily on third parties for manufacturing and supply of raw materials, such as 212 Pb , which increases the risk of insufficient quantities or unacceptable costs, potentially delaying or impairing development and commercialization efforts . Intellectual property risks include the inability to obtain and maintain broad patent protection, which could allow competitors to commercialize similar products , and the potential for costly and time-consuming litigation if sued for infringing third-party intellectual property rights . Geopolitical risks, including evolving impacts from tariffs, sanctions, or other trade tensions, or demand/supply shocks from events like war or natural disasters, could disrupt supply chains and increase costs . Cybersecurity threats, including cyber-attacks and data breaches, pose risks of regulatory investigations, litigation, fines, and business disruptions . Changes in healthcare legislative reform measures, such as the One Big Beautiful Bill Act (OBBBA) signed on July 4, 2025 , which narrowed access to ACA marketplace exchange enrollment and declined to extend ACA enhanced advanced premium tax credits that expired at the end of 2025 , could negatively impact the business and results of operations by limiting reimbursement or increasing pricing pressures .

Management Priorities

Management's message to shareholders emphasizes a strategic reprioritization of the clinical portfolio, announced in March 2026, to focus on promising next-generation therapeutics, specifically nuzefatide pevedotin and next-generation Bicycle conjugates, including BRC molecules . This strategic shift involves converting the Phase II/III Duravelo-2 registrational trial for zelenectide pevedotin to a randomized Phase II clinical trial and deprioritizing the program for internal development, while discontinuing Phase I/II clinical trials for zelenectide pevedotin in NECTIN4 amplified advanced breast cancer and non-small cell lung cancer . A key strategic priority is to reduce annual operating expenses by approximately 50% through this reprioritization and a proposed workforce reduction of approximately 30% of the workforce, which is expected to be substantially completed by the end of 2026 and incur aggregate charges of approximately $8.0 million . Management believes that the existing cash and cash equivalents of $628.1 million as of December 31, 2025, will enable the company to fund its operating expenses and capital expenditure requirements for at least 12 months from the date of filing of this Annual Report .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Introduction to Bicycle molecules
  2. [2] Item 1, Business — Our Strategy
  3. [3] Item 1A, Risk Factors — Risks Related to Our Financial Position and Need for Additional Capital
  4. [4] Item 1, Business — Our Internal Programs
  5. [5] Item 1, Business — Our Internal Programs
  6. [6] Item 1, Business — Our Internal Programs
  7. [7] Item 1, Business — Zelenectide Pevedotin
  8. [8] Item 1, Business — Zelenectide Pevedotin
  9. [9] Item 1, Business — BT7480
  10. [10] Item 1A, Risk Factors — We have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future, and we may never achieve or maintain profitability.
  11. [11] Item 1A, Risk Factors — We have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future, and we may never achieve or maintain profitability.
  12. [12] Item 1A, Risk Factors — We have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future, and we may never achieve or maintain profitability.
  13. [13] Item 1A, Risk Factors — We may need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.
  14. [14] Item 1, Business — Zelenectide Pevedotin
  15. [15] Item 1, Business — Zelenectide Pevedotin
  16. [16] Item 1A, Risk Factors — Our recent workforce reductions were undertaken to significantly reduce our ongoing operating expenses, but they may not result in our intended outcomes and may yield unintended consequences and additional costs.
  17. [17] Item 1A, Risk Factors — Our recent workforce reductions were undertaken to significantly reduce our ongoing operating expenses, but they may not result in our intended outcomes and may yield unintended consequences and additional costs.
  18. [18] Item 1, Business — Zelenectide Pevedotin
  19. [19] Item 1, Business — Zelenectide Pevedotin
  20. [20] Item 1, Business — Nuzefatide pevedotin
  21. [21] Item 1, Business — Nuzefatide pevedotin
  22. [22] Item 1, Business — Nuzefatide pevedotin
  23. [23] Item 1, Business — BT1702
  24. [24] Item 1, Business — Our Strategy
  25. [25] Item 1, Business — Bicycle Radioligands Pipeline
  26. [26] Item 1, Business — Bicycle Radioligands Pipeline
  27. [27] Item 1, Business — Bicycle Radioligands Pipeline
  28. [28] Item 1, Business — Zelenectide Pevedotin
  29. [29] Item 1A, Risk Factors — Our recent workforce reductions were undertaken to significantly reduce our ongoing operating expenses, but they may not result in our intended outcomes and may yield unintended consequences and additional costs.
  30. [30] Item 1, Business — Our Strategy
  31. [31] Item 1, Business — Ionis
  32. [32] Item 1A, Risk Factors — We may need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.
  33. [33] Item 1A, Risk Factors — We have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future, and we may never achieve or maintain profitability.
  34. [34] Item 1A, Risk Factors — We may need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.
  35. [35] Item 1A, Risk Factors — We are substantially dependent on the success of our internal development programs and of our product candidates from our BDC and BRC programs, which may not successfully complete clinical trials, receive regulatory approval or be successfully commercialized.
  36. [36] Item 1A, Risk Factors — We are at an early stage in our development efforts, and our product candidates and those of our collaborators represent a new category of medicines and may be subject to heightened regulatory scrutiny until they are established as a therapeutic modality.
  37. [37] Item 1A, Risk Factors — We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.
  38. [38] Item 1A, Risk Factors — Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.
  39. [39] Item 1A, Risk Factors — Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs, or IND, that could halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences.
  40. [40] Item 1A, Risk Factors — We may be delayed or not be successful in our efforts to identify or discover additional product candidates.
  41. [41] Item 1A, Risk Factors — We have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future, and we may never achieve or maintain profitability.
  42. [42] Item 1A, Risk Factors — We have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future, and we may never achieve or maintain profitability.
  43. [43] Item 1A, Risk Factors — We are substantially dependent on the success of our internal development programs and of our product candidates from our BDC and BRC programs, which may not successfully complete clinical trials, receive regulatory approval or be successfully commercialized.
  44. [44] Item 1A, Risk Factors — We are at an early stage in our development efforts, and our product candidates and those of our collaborators represent a new category of medicines and may be subject to heightened regulatory scrutiny until they are established as a therapeutic modality.
  45. [45] Item 1A, Risk Factors — We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates.
  46. [46] Item 1A, Risk Factors — Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.
  47. [47] Item 1A, Risk Factors — Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences.
  48. [48] Item 1A, Risk Factors — We intend to rely on third parties to manufacture product candidates and supply raw materials used in our product candidates, such as 212 Pb, which increases the risk that we will not have sufficient quantities of such product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
  49. [49] Item 1A, Risk Factors — We intend to rely on third parties to manufacture product candidates and supply raw materials used in our product candidates, such as 212 Pb, which increases the risk that we will not have sufficient quantities of such product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
  50. [50] Item 1A, Risk Factors — If we are unable to obtain and maintain patent and other intellectual property protection for our products and product candidates, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products and product candidates may be adversely affected.
  51. [51] Item 1A, Risk Factors — If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.
  52. [52] Item 1A, Risk Factors — As a company with operations outside of the United States, we are subject to economic, political, regulatory and other risks associated with international operations.
  53. [53] Item 1A, Risk Factors — Cyber-attacks, failures in or interruptions of, or other compromise to our information technology systems, or those of third parties with whom we work, or our data could result in adverse consequences that materially affect our business, including without limitation, regulatory investigations or actions, litigation, fines and penalties, information theft, data corruption, harm to our reputation and brand, significant disruption of our business operations, and other adverse consequences.
  54. [54] Item 1A, Risk Factors — Healthcare legislative reform measures may have a negative impact on our business and results of operations.
  55. [55] Item 1A, Risk Factors — Healthcare legislative reform measures may have a negative impact on our business and results of operations.
  56. [56] Item 1A, Risk Factors — Healthcare legislative reform measures may have a negative impact on our business and results of operations.
  57. [57] Item 1, Business — Zelenectide Pevedotin
  58. [58] Item 1, Business — Zelenectide Pevedotin
  59. [59] Item 1A, Risk Factors — Our recent workforce reductions were undertaken to significantly reduce our ongoing operating expenses, but they may not result in our intended outcomes and may yield unintended consequences and additional costs.
  60. [60] Item 1A, Risk Factors — We may need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.
  61. [61] Item 1A, Risk Factors — We may need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.

Analysis on 5/22/2026